Drugs / GC1111
GC1111
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01301898 | May 2010 → Mar 2011 | mucopolysaccharidosis type 2 | Green Cross Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03920540 | Mar 2017 → Feb 2022 | Hunter-Macdonald syndrome | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC1111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03920540 ↗ |
| Known as | Hunterase | “The objective of this phase I/II clinical study was to evaluate the efficacy and safety of recombinant human iduronate-2-sulfatase (idursulfase beta, Hunterase®) in the...” PMID 23497636 ↗ Mar 2013 |
| Known as | idursulfase beta | “The objective of this phase I/II clinical study was to evaluate the efficacy and safety of recombinant human iduronate-2-sulfatase (idursulfase beta, Hunterase®) in the...” PMID 23497636 ↗ Mar 2013 |
| Action | Restore | “enzyme replacement therapy with idursulfase beta” PMID 23497636 ↗ Mar 2013 |
| Modality | Protein / enzyme biologic | “recombinant human iduronate-2-sulfatase” NCT01301898 ↗ |